Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1977-6-22
|
| pubmed:abstractText |
1. The beta1-adrenoreceptor-blocking agent atenolol was studied in the treatment of twelve out-patients with essential hypertension. 2. With a mean dose of 110 mg of atenolol daily (range 75-200 mg/day) we observed a pronounced decrease in blood pressure. 3. Only minimal side effects were seen. 4. Cardiac output decreased from 4-6 to 3-4 l/min during treatment. This decrease did not correlate with the decrease in blood pressure but correlated well with the changes in calculated total peripheral resistance.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0144-4107
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
3
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
525s-526s
|
| pubmed:dateRevised |
2008-2-12
|
| pubmed:meshHeading |
pubmed-meshheading:799562-Adult,
pubmed-meshheading:799562-Atenolol,
pubmed-meshheading:799562-Cardiac Output,
pubmed-meshheading:799562-Clinical Trials as Topic,
pubmed-meshheading:799562-Female,
pubmed-meshheading:799562-Humans,
pubmed-meshheading:799562-Hypertension,
pubmed-meshheading:799562-Male,
pubmed-meshheading:799562-Middle Aged,
pubmed-meshheading:799562-Propanolamines
|
| pubmed:year |
1976
|
| pubmed:articleTitle |
Clinical and haemodynamic study of atenolol (Tenormin) in essential hypertension.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|